> INVESTORS   Overview   Corporate Structure   Corporate Governance   Company History   Annual General Meeting   Postal Ballot   Investor FAQs   Stock Info   Financial Results   Subsidiary Financials   Annual Report   Disclosure to Stock Exchange   Nomination form   Press Releases   Presentations   Analyst Coverage   Investor Contacts

Disclosure to Stock Exchange   September 2020 03 Sep Meetings conducted with Institutional Investors/Research Analysts 03 Sep Allotment of shares by BBIL to Tata Capital   August 2020 31 Aug Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes 21 Aug Intimation pursuant to Regulation 30 of SEBI Listing Regulations, amendment in Memorandum of Association of the Company 20 Aug Meetings conducted with Institutional Investors/Research Analysts 14 Aug Disclosure of material impact of COVID 19 pandemic on the Company 14 Aug Meetings conducted with Institutional Investors/Research Analysts. 12 Aug Meetings conducted with Institutional Investors/Research Analysts. 10 Aug Meetings conducted with Institutional Investors/Research Analysts. 05 Aug Meetings conducted with Institutional Investors/Research Analysts. 04 Aug Meetings conducted with Institutional Investors/Research Analysts. 03 Aug Execution of SHA and SSA with Tata Capital Growth Fund II - Disclosure pursuant to Regulation 30 of SEBI Regulations, 2015   July 2020 31 July Tata Capital Growth Fund to Invest ~USD 30 Million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85%, Deal Values Biocon Biologics at USD 3.5 Billion 25 July Voting results and scrutinizers’ report of the 42nd Annual General Meeting (‘AGM’) of Biocon Limited (‘the Company’) 25 July Proceedings of the 42nd Annual General Meeting (‘AGM’) of Biocon Limited (‘the Company’). 23 July Press Release on financial results for the quarter ended June 30, 2020. 23 July Outcome of the Board Meeting 21 July Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins 11 July Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for Emergency Use in Moderate to Severe COVID-19 Patients 09 July Notice of Board Meeting - Newspaper Advertisement 07 July Intimation for the Board Meeting and Trading Window Closure 02 July Newspaper Advertisement – Notice of 42nd AGM and the Annual Report for the FY 2019-20. 02 July Notice of 42nd Annual General Meeting and the Annual Report for the FY 2019-20.   June 2020 30 June Meetings conducted with Institutional Investors / Research Analysts. 26 June Newspaper Advertisement - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”). 26 June Meetings conducted with Institutional Investors / Research Analysts. 25 June Meetings conducted with Institutional Investors / Research Analysts. 24 June Newspaper Advertisement for transfer of equity shares to IEPF 22 June Biocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets 18 June Meetings conducted with Institutional Investors / Research Analysts. 15 June Meetings conducted with Institutional Investors / Research Analysts. 12 June Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection) 12 June Meetings conducted with Institutional Investors / Research Analysts. 11 June Disclosure of Related Party Transactions for the half year ended March 31, 2020 11 June Meeting conducted with Institutional Investors / Research Analysts 11 June Investor Presentation on "Biocon Biologics - Transforming Healthcare. Transforming Lives." 09 June Meetings conducted with Institutional Investors / Research Analysts. 08 June Investor Presentation 05 June Kiran Mazumdar-Shaw wins EY World Entrepreneur of the Year™ 2020 Award. She is the first woman entrepreneur from India and third Indian to win this title in WEOY Award’s 20-year History 05 June Meetings conducted with Institutional Investors / Research Analysts 04 June Meetings conducted with Institutional Investors / Research Analysts. 02 June Meeting conducted with Institutional Investors / Research Analysts. 01 June Meeting conducted with Institutional Investors / Research Analysts 01 June Biocon's* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi's Four Device Patents for Lantus® SoloSTAR®   May 2020 29 May Meetings conducted with Institutional Investors / Research Analysts 27 May Meeting conducted with Institutional Investors / Research Analysts. 27 May Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients U.S. FDA recently approved CytoSorb for emergency use in COVID-19 patients 21 May Meetings conducted with Institutional Investors / Research Analysts. 20 May Meeting conducted with Institutional Investors / Research Analysts 19 May Meeting conducted with Institutional Investors / Research Analysts 19 May Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity Includes Drug Substance and Drug Product Facilities for Pegfilgrastim, Trastuzumab, and Bevacizumab 14 May Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr 14 May Outcome of the Board Meeting 14 May Appointment of Interim Chief Financial Officer (‘Interim CFO’) and Key Managerial Personnel of the Company 12 May Company Statement: Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification 08 May Company Statement: Biocon's Receives EIR for Small Molecules API Manufacturing Facility for Pre -Approval and GMP U.S. FDA Inspection   April 2020 28 Apr Biocon and Mylan Launch Fulphila®d, Biosimilar Pegfilgrastim, in Canada. 22 Apr Intimation for the Board Meeting and Trading Window Closure 20 Apr Meeting conducted with Institutional Investors/Research Analysts 16 Apr Company Statement : Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed 14 Apr Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia 02 Apr Meeting conducted with Institutional Investors/Research Analysts. 01 Apr Biocon's Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed   March 2020 27 Mar Biocon & Biocon Biologics Ensuring Manufacturing of Life-Saving Medicines for Patients, Partners and Customers 20 Mar Company Statement: Biocon Receives EIR for Small Molecules API Manufacturing Facility for Post - Approval and GMP U.S. FDA Inspection 13 Mar Meetings conducted with Institutional Investors / Analysts. 11 Mar Biocon & Mylan Win Patent Litigation Asserted by Sanofi for Insulin Glargine Device Patent in U.S. 09 Mar Meeting conducted with Institutional Investors / Analysts. 09 Mar U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review 06 Mar Meeting conducted with Institutional Investors / Analysts.   February 2020 27 Feb Biocon's Small Molecules API Manufacturing Facility Completes Post-Approval and GMP U.S. FDA Inspection 26 Feb Meeting conducted with Institutional Investors / Analysts 22 Feb Company Statement: Biocon's Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection 19 Feb Meetings conducted with Institutional Investors / Analysts 18 Feb Meetings conducted with Institutional Investors / Analysts 12 Feb Meeting conducted with Institutional Investors / Analysts 10 Feb Investor Presentation 07 Feb Amalgamation of Biocon Research Limited ("BRL") with Biocon Biologics India Limited ("BBIL")   January 2020 30 Jan Meeting conducted with Institutional Investors / Analysts 27 Jan Company statement: Biocon's API Manufacturing Facility Completes Pre-Approval and GMP U.S. FDA inspection 23 Jan Change in the name and contact details of Key Managerial Personnel under the Policy for Determination of Materiality for Disclosures 23 Jan Change in Directorate 23 Jan Biocon Q3FY20 Earnings Revenue at Rs 1,784 Cr, Up 14%; EBITDA at Rs 480 Cr, Up 18%; Net Profit (before exceptional item) at Rs 225 Cr, Up 6% 23 Jan Outcome of the Board Meeting 21 Jan Allotment of shares by BBIL to Activ Pine LLP 20 Jan Biocon's Oral Solid Dosage Manufacturing Facility Completes Pre-Approval U.S. FDA lnspection with Zero Observations 09 Jan Execution of SHA and SSA with True North - Disclosure pursuant to Regulation 30 of SEBI Regulations, 2015 06 Jan Notice of Board Meeting- Newspaper Advertisement 06 Jan Press Release 06 Jan True North to Invest Rs 536.25 Crore in Biocon Biologics for 2.44% Stake 03 Jan Intimation of Board Meeting and Trading Window Closure

January to July 2020  January to December 2019  January to December 2018  January to December 2017  January to December 2016  December 2015

Biocon Businesses Recommended sites Biocon on     Home About Us Investor Relations Media Relations Careers Site Map Contact Us Our Growth Accelerators Fact Sheet Branded Formulations Biopharmaceuticals Research Services Active Discovery Program ABLE Karnataka Vision Group on BT Syngene International Biocon Academy                   Report adverse event/side effects and product complaints               * Disclaimer            © 2018, Biocon. All Rights Reserved